RNXT vs. RMTI, CALC, AMLX, KPTI, CLRB, ADAG, COYA, PDSB, DMAC, and CYTT
Should you be buying RenovoRx stock or one of its competitors? The main competitors of RenovoRx include Rockwell Medical (RMTI), CalciMedica (CALC), Amylyx Pharmaceuticals (AMLX), Karyopharm Therapeutics (KPTI), Cellectar Biosciences (CLRB), Adagene (ADAG), Coya Therapeutics (COYA), PDS Biotechnology (PDSB), DiaMedica Therapeutics (DMAC), and Cyteir Therapeutics (CYTT). These companies are all part of the "pharmaceutical preparations" industry.
Rockwell Medical (NASDAQ:RMTI) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
In the previous week, Rockwell Medical had 1 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Rockwell Medical and 3 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.97 beat Rockwell Medical's score of 0.30 indicating that Rockwell Medical is being referred to more favorably in the media.
23.3% of Rockwell Medical shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 1.9% of Rockwell Medical shares are held by company insiders. Comparatively, 7.1% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
RenovoRx has a net margin of 0.00% compared to RenovoRx's net margin of -9.72%. RenovoRx's return on equity of -28.29% beat Rockwell Medical's return on equity.
Rockwell Medical has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
Rockwell Medical currently has a consensus target price of $7.00, indicating a potential upside of 298.86%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 632.76%. Given Rockwell Medical's higher possible upside, analysts plainly believe RenovoRx is more favorable than Rockwell Medical.
Rockwell Medical received 296 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 57.31% of users gave Rockwell Medical an outperform vote while only 37.50% of users gave RenovoRx an outperform vote.
Rockwell Medical has higher revenue and earnings than RenovoRx. Rockwell Medical is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.
Summary
Rockwell Medical beats RenovoRx on 12 of the 16 factors compared between the two stocks.
Get RenovoRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNXT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RenovoRx Competitors List
Related Companies and Tools
